Show simple item record

dc.contributor.authorKhwairakpam, G
dc.contributor.authorBurry, J
dc.date.accessioned2019-02-26T17:28:55Z
dc.date.available2019-02-26T17:28:55Z
dc.date.issued2019-01
dc.date.submitted2018-12-13
dc.identifier.citationStrategies for access to affordable hepatitis C testing and treatment in Asia. 2019, 14 (1):1-6 Curr Opin HIV AIDSen_US
dc.identifier.issn1746-6318
dc.identifier.pmid30480583
dc.identifier.doi10.1097/COH.0000000000000514
dc.identifier.urihttp://hdl.handle.net/10144/619347
dc.description.abstractWith increasing availability of generic direct-acting antivirals (DAAs) and associated price reductions, various governments, multilateral institutions, and donors have started providing testing and treatment for hepatitis C virus (HCV) infection. More data on the quality of these generic medicines and on cost-effectiveness of their use are becoming widely available. This review seeks to describe some of the treatment programs for HCV that are evolving in Cambodia, India, Indonesia, Malaysia, Myanmar, and Thailand.en_US
dc.language.isoenen_US
dc.rightsWe regret that this article is behind a paywall.en_US
dc.titleStrategies for access to affordable hepatitis C testing and treatment in Asiaen_US
dc.identifier.journalCurrent Opinion in HIV and AIDSen_US


This item appears in the following Collection(s)

Show simple item record